Key Points
- Insider sale: Enliven insider Joseph Lyssikatos sold 5,000 shares on Feb. 6 at an average $29.04 for $145,200, leaving him with 740,188 shares — a 0.67% reduction in ownership.
- Market snapshot: ELVN trades near $27.93 (12‑month range $13.30–$30.22), has a market cap of $1.66 billion and a negative PE of -15.18, with 50‑ and 200‑day moving averages around $21.78 and $20.77.
- Analyst and earnings outlook: the company reported a smaller-than-expected quarterly loss of ($0.32), analysts expect a -1.95 EPS for the year, and the consensus rating is a "Moderate Buy" with a consensus target price of $41.
Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph Lyssikatos sold 5,000 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $29.04, for a total value of $145,200.00. Following the transaction, the insider owned 740,188 shares of the company's stock, valued at approximately $21,495,059.52. This represents a 0.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.
Enliven Therapeutics Trading Down 0.5%
Shares of NASDAQ:ELVN opened at $27.93 on Wednesday. Enliven Therapeutics, Inc. has a 12-month low of $13.30 and a 12-month high of $30.22. The business has a 50 day moving average of $21.78 and a two-hundred day moving average of $20.77. The company has a market capitalization of $1.66 billion, a PE ratio of -15.18 and a beta of 0.34.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.11. Equities research analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Enliven Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company's stock valued at $44,000 after buying an additional 594 shares during the last quarter. Invesco Ltd. boosted its position in Enliven Therapeutics by 4.3% during the second quarter. Invesco Ltd. now owns 21,957 shares of the company's stock worth $440,000 after acquiring an additional 913 shares during the last quarter. BNP Paribas Financial Markets grew its stake in Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company's stock valued at $75,000 after acquiring an additional 930 shares in the last quarter. Quantbot Technologies LP grew its stake in Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company's stock valued at $90,000 after acquiring an additional 1,434 shares in the last quarter. Finally, Legal & General Group Plc raised its holdings in Enliven Therapeutics by 4.8% in the 3rd quarter. Legal & General Group Plc now owns 33,765 shares of the company's stock valued at $691,000 after acquiring an additional 1,540 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on ELVN shares. Wall Street Zen upgraded shares of Enliven Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, November 15th. Weiss Ratings restated a "sell (d-)" rating on shares of Enliven Therapeutics in a research note on Wednesday, January 21st. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $41.00.
View Our Latest Report on Enliven Therapeutics
About Enliven Therapeutics
(
Get Free Report)
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.
The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
